Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States.
Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
The company was founded in 2014 and is based in Paramus, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 26 | -0.16 | -0.02 Decreased by -700.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | N/A Decreased by N/A% | -1.50 M Decreased by -106.78% | - - |
| Sep 30, 25 | 0.00 Decreased by N/A% | -1.43 M Decreased by -85.47% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 - | -1.01 M - | Decreased by N/A% - |
| Mar 31, 25 | 0.00 - | -5.05 M - | Decreased by N/A% - |
| Dec 31, 24 | 0.00 - | -723.00 K - | Decreased by N/A% - |
| Sep 30, 24 | 0.00 - | -771.00 K - | Decreased by N/A% - |